FDA Approves Rytelo for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia June 6, 2024 – Geron Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Rytelo™ (imetelstat) for the treatment of adult patients:
• with low- to intermediate-1 risk myelodysplastic syndromes (MDS),
• with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks,
• who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Rytelo is a first-in-class treatment that works by inhibiting telomerase enzymatic activity, and It is indicated to be administered as an intravenous infusion over two hours every four weeks.
Source: Geron Corporation
